MedTrace Logo

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

NCT00810485 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 298

Last updated 2012-07-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

ADX10059

oral administration

DRUG

ADX10059

oral administration

DRUG

ADX10059

oral administration

DRUG

ADX10059 Matching Placebo

oral administration

Sponsors & Collaborators

  • Addex Pharma S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-12-31

Countries

  • United States
  • France
  • Germany
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00810485 on ClinicalTrials.gov